Analysis of T lymphocytes cytokine profiles allows to differ subpopulations: Th1, Th2, Th3, Tr1. Aim of the study was to assess Th1/Th2 balance in acute lymphoblastic leukemia in children at diagnosis and during/after remission induction, especially during infections. Percentages of lymphocytes T producing IFN-gamma and IL-4 were assessed by flow cytometry. We noted the rise of lymphocytes T helper producing IFN-gamma (Th1) and percentage of lymphocytes T producing IL-4 at the beginning and during remission induction was higher than in control group. During fever/infection we observed the rise of lymphocytes Th1, and no change in Th2 percentage. Summarizing we suggest Th1/Th2 imbalance and Th2 predominance in acute lymphoblastic leukemia in children.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Status of IKZF1 Deletions in Diagnose and Relapsed Pediatric B-ALL Patients.
Biochem Genet
January 2025
Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Topkapı mh, Gureba Hastanesi Cd. No:69, 34093, Fatih, Istanbul, Turkey.
IKZF1 deletions (ΔIKZF1) are common in precursor B-cell acute lymphoblastic leukemia (B-ALL) and are assumed to have a prognostic impact. We aimed to determine the prognostic implications of ΔIKZF1 and CRLF2 overexpression in pediatric B-ALL. Furthermore, we sought to compare the multiplex polymerase chain reaction (PCR) assay with standard multiplex ligand-dependent probe amplification (MLPA) methods to ascertain IKZF1 status in a clinical context.
View Article and Find Full Text PDFPrognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALL.
Blood
December 2024
St. Jude Children's Research Hospital, Memphis, Tennessee, United States.
We evaluated the prognostic and therapeutic significance of measurable residual disease (MRD) during remission induction in pediatric acute lymphoblastic leukemia (ALL) patients. In the CCCG-ALL-2015 protocol, 7640 patients were categorized into low-, intermediate-, or high-risk groups based on clinical and genetic features. Final risk classification was determined by MRD assessed via flow cytometry on Days 19 and 46 of remission induction, with additional intensified chemotherapy for Day 19 MRD ≥1%.
View Article and Find Full Text PDFGenetic subtypes of B-cell acute lymphoblastic leukemia in adults.
Blood
December 2024
Université Paris-Cité, Institut de Recherche Saint-Louis, INSERM U944, France.
B-cell acute lymphoblastic leukemia (B-ALL) is a rare malignancy in adults with outcomes remaining poor, especially compared to children. Over the past two decades, extensive whole-genome studies have identified numerous genetic alterations driving leukemia, leading to the recognition of more than 20 distinct subtypes which are closely associated with treatment response and prognosis. In pediatric B-ALL, large correlation studies have made genetic classification a central component of risk-adapted treatment strategies.
View Article and Find Full Text PDFTargeting WDR5/ATAD2 signaling by the CK2/Ikaros axis demonstrates therapeutic efficacy in T-ALL.
Blood
December 2024
Department of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with a poor prognosis and limited options for targeted therapies. Identifying new molecular targets to develop novel therapeutic strategies is the pressing immediate issue in T-ALL. Here, we observed high expression of WD Repeat-Containing Protein 5 (WDR5) in T-ALL; with in vitro and in vivo models we demonstrated the oncogenic role of WDR5 in T-ALL by activating cell cycle signaling through its new downstream effector, ATPase family AAA domain-containing 2 (ATAD2).
View Article and Find Full Text PDFRelapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.
Haematologica
January 2025
Division of Oncology, the Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
While outcomes for pediatric acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) have improved dramatically in recent decades, relapsed and refractory disease remain a significant therapeutic challenge. This is particularly true for patients with T-cell ALL and LBL, where survival for patients with relapsed/refractory disease remains dismal. Recent efforts to comprehensively profile the genomics of T-ALL/LBL to improve understanding of disease biology have enhanced our ability to identify high-risk patients at diagnosis who are more likely to relapse and have also identified novel targets for precision medicines.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!